SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-13-027688
Filing Date
2013-05-10
Accepted
2013-05-10 09:52:41
Documents
11
Period of Report
2013-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v341798_10q.htm 10-Q 293729
2 EXHIBIT 31.1 v341798_ex31-1.htm EX-31.1 7874
3 EXHIBIT 31.2 v341798_ex31-2.htm EX-31.2 8153
4 EXHIBIT 32.1 v341798_ex32-1.htm EX-32.1 3774
5 EXHIBIT 32.2 v341798_ex32-2.htm EX-32.2 3817
  Complete submission text file 0001144204-13-027688.txt   2767240

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT navb-20130331.xml EX-101.INS 228643
8 XBRL TAXONOMY EXTENSION SCHEMA navb-20130331.xsd EX-101.SCH 33247
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20130331_cal.xml EX-101.CAL 42009
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20130331_def.xml EX-101.DEF 122652
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20130331_lab.xml EX-101.LAB 468280
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20130331_pre.xml EX-101.PRE 229468
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 13831423
SIC: 2835 In Vitro & In Vivo Diagnostic Substances